KELSEY CUMMINGS: Open Payments
NPI 1700669686 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$270 in 8 payments from 7 companies in 2025. Trend: 2023 $33 · 2024 $482 · 2025 $270
Food & beverage: $270
| Company | Payments | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | 1 | $106 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $43 |
| Astellas Pharma US Inc | 1 | $30 |
| Merck Sharp & Dohme LLC | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Veloxis Pharmaceuticals, Inc. | 1 | $23 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $16 |
Products named: ULTOMIRIS, XIFAXAN, Cresemba, PREVYMIS, IQIRVO, ENVARSUS, Kerendia.
Industry payments across DC — which companies pay providers there.
